Cancer is the second most common cause of death worldwide. Even though great advances have been made in the last decades, the current therapeutic options are still poorly effective for a large portion of cancer patients. Poor response and development of resistance to therapy are the main cause of current cancer treatment failure, resulting in an urgent need for groundbreaking therapeutic solutions.

THERAtRAME has developed an innovative discovery platform to create and develop novel therapeutic agents to beat untreatable or resistant cancers. The company is building on the pioneering discoveries of its founders to develop first-in-class drugs targeting the tRNA epitranscriptomics. Their approach integrates hardcore drug discovery activities with unique proprietary screening technologies and AI-based mathematical models to exploit the potential of tRNA epitranscriptomics as a transversal target space in oncology.

THERAtRAME is a spin-off company of the University of Liège (ULiège) and WELBIO that aims to translate the breakthrough discoveries made by its founders on the importance of tRNA epitranscriptomics in cancer into novel therapeutic strategies. This pioneering work results from over a decade of fundamental research performed at ULiège, with the support of WELBIO, the Belgian Foundation against Cancer and FNRS. The founder team was able to attract key business profiles and investors to guide the translation of its cutting-edge science into concrete solutions for the benefit of patients.

THERAtRAME has the ambition to become the world leader in providing and positioning new therapeutics against tRNA epitranscriptomics. Its unique platform approach has the potential to strongly contribute to major advances in cancer therapy by partnering with prominent pharma actors in oncology.